Equities

Akebia Therapeutics Inc

Akebia Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.37
  • Today's Change0.000 / 0.00%
  • Shares traded3.56m
  • 1 Year change+14.17%
  • Beta0.7717
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

  • Revenue in USD (TTM)174.50m
  • Net income in USD-40.44m
  • Incorporated2007
  • Employees167.00
  • Location
    Akebia Therapeutics Inc245 First StreetCAMBRIDGE 02142United StatesUSA
  • Phone+1 (617) 871-2098
  • Fax+1 (617) 871-2099
  • Websitehttps://akebia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mersana Therapeutics Inc29.94m-104.77m268.66m123.00--31.88--8.97-0.8648-0.86480.24690.06870.1222--38.14243,390.30-42.75-61.68-59.36-81.35-----349.98-622.19----0.7508--38.6528.3215.94--9.61--
Black Diamond Therapeutics Inc0.00-80.55m270.09m54.00--2.43-----1.54-1.540.001.970.00----0.00-59.70-40.29-67.82-43.29------------0.00------9.57---15.37--
Vanda Pharmaceuticals Inc.182.02m-10.93m271.05m203.00--0.4996--1.49-0.1886-0.18863.159.310.28159.964.82896,660.10-1.696.61-1.977.6293.0390.55-6.0015.184.67--0.000.00-24.27-0.0496-60.02-36.96-56.77--
Zura Bio Ltd0.00-27.94m274.23m14.00--1.75-----0.4944-0.49440.002.460.00----0.00-23.00---30.30--------------0.0136-------2,050.99------
Chromadex Corp85.58m-1.35m280.95m106.00--9.09--3.28-0.018-0.0181.140.4071.602.8612.93807,386.80-2.52-42.11-3.85-65.1460.8259.68-1.58-30.642.12--0.0006--15.9921.5070.15---36.66--
AVITA Medical Inc54.14m-49.83m281.47m207.00--11.75--5.20-1.95-1.952.120.92160.62171.467.23261,541.10-57.22---68.00--86.80---92.04--4.81-13.950.6315--45.68---32.69------
Artiva Biotherapeutics Inc-100.00bn-100.00bn284.89m82.00--------------1.09----------------------------0.0087--579.21--51.15------
ESSA Pharma Inc0.00-27.67m287.51m50.00--2.23-----0.6257-0.62570.002.900.00----0.00-19.33-23.01-19.81-23.67------------0.00------24.27------
Akebia Therapeutics Inc174.50m-40.44m288.09m167.00------1.65-0.2024-0.20240.8803-0.16080.73641.367.071,044,892.00-17.07-37.42-29.47-56.0082.5969.13-23.18-82.250.8222-4.418.89---33.46-1.3044.89------
Tectonic Therapeutic Inc0.00-58.25m291.74m13.00--1.75-----18.52-18.520.0011.290.00----0.00-35.55-45.22-40.16-49.14-----------128.750.0066------111.48---66.27--
Kyverna Therapeutics Inc-100.00bn-100.00bn298.58m112.00--0.8953----------7.73----------------------------0.0042---100.00---108.93------
Tscan Therapeutics Inc12.20m-104.41m298.77m175.00--1.17--24.49-1.05-1.050.12254.820.0353----79,220.78-30.19---33.78-------855.84------0.1066--55.52---34.73------
PepGen Inc0.00-89.14m304.71m64.00--1.95-----3.30-3.300.004.780.00----0.00-47.47---52.97--------------0.00-------13.78------
Heron Therapeutics Inc136.36m-48.13m306.37m126.00------2.25-0.3249-0.32490.9094-0.25030.65031.081.811,082,230.00-22.95-53.55-38.15-71.2465.4952.52-35.29-170.121.85--1.34--17.9910.4039.26---29.97--
Solid Biosciences Inc0.00-90.69m308.76m88.00--1.60-----3.30-3.300.005.010.00----0.00-41.63-49.99-44.77-56.25-------2,117.05----0.0076---100.00---11.67---27.90--
Data as of Sep 20 2024. Currency figures normalised to Akebia Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

19.52%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 202410.93m5.20%
The Vanguard Group, Inc.as of 30 Jun 20249.10m4.33%
Geode Capital Management LLCas of 30 Jun 20244.54m2.16%
Acadian Asset Management LLCas of 30 Jun 20244.06m1.93%
Renaissance Technologies LLCas of 30 Jun 20243.91m1.86%
SSgA Funds Management, Inc.as of 30 Jun 20242.75m1.31%
Jacobs Levy Equity Management, Inc.as of 30 Jun 20242.09m1.00%
Qube Research & Technologies Ltd.as of 30 Jun 20241.74m0.83%
Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 20241.05m0.50%
Federated MDTA LLCas of 30 Jun 2024865.25k0.41%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.